RHYTHM PHARMACEUTICALS INC
NASDAQ: RYTM (Rhythm Pharmaceuticals, Inc.)
Last update: 2 hours ago96.06
-2.48 (-2.52%)
| Previous Close | 98.54 |
| Open | 98.77 |
| Volume | 1,066,930 |
| Avg. Volume (3M) | 726,325 |
| Market Cap | 6,380,314,112 |
| Price / Sales | 38.34 |
| Price / Book | 84.89 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -123.28% |
| Operating Margin (TTM) | -143.73% |
| Diluted EPS (TTM) | -2.80 |
| Quarterly Revenue Growth (YOY) | 25.90% |
| Total Debt/Equity (MRQ) | 69.65% |
| Current Ratio (MRQ) | 3.30 |
| Operating Cash Flow (TTM) | -113.49 M |
| Levered Free Cash Flow (TTM) | -96.71 M |
| Return on Assets (TTM) | -51.33% |
| Return on Equity (TTM) | -150.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Rhythm Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | 1.00 |
|
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.65% |
| % Held by Institutions | 103.78% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Baker Bros. Advisors Lp | 30 Jun 2025 | 5,604,483 |
| Ra Capital Management, L.P. | 30 Jun 2025 | 5,561,359 |
| Primecap Management Co/Ca/ | 30 Jun 2025 | 4,878,037 |
| Nea Management Company, Llc | 30 Jun 2025 | 2,909,956 |
| Perceptive Advisors Llc | 30 Jun 2025 | 2,418,299 |
| Federated Hermes, Inc. | 30 Jun 2025 | 1,686,494 |
| Westfield Capital Management Co Lp | 30 Jun 2025 | 1,629,468 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 135.00 (JMP Securities, 40.54%) | Buy |
| Median | 107.00 (11.39%) | |
| Low | 95.00 (B of A Securities, -1.10%) | Buy |
| 95.00 (Needham, -1.10%) | Buy | |
| Average | 110.00 (14.51%) | |
| Total | 10 Buy | |
| Avg. Price @ Call | 89.69 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 07 Aug 2025 | 100.00 (4.10%) | Buy | 92.48 |
| Guggenheim | 06 Aug 2025 | 120.00 (24.92%) | Buy | 90.01 |
| JMP Securities | 06 Aug 2025 | 135.00 (40.54%) | Buy | 90.01 |
| 26 Jun 2025 | 84.00 (-12.55%) | Buy | 61.45 | |
| Morgan Stanley | 06 Aug 2025 | 109.00 (13.47%) | Buy | 90.01 |
| Canaccord Genuity | 18 Jul 2025 | 105.00 (9.31%) | Buy | 89.20 |
| B of A Securities | 10 Jul 2025 | 95.00 (-1.10%) | Buy | 89.04 |
| Leerink Partners | 10 Jul 2025 | 102.00 (6.18%) | Buy | 89.04 |
| 07 Jul 2025 | 88.00 (-8.39%) | Buy | 66.39 | |
| Oppenheimer | 10 Jul 2025 | 110.00 (14.51%) | Buy | 89.04 |
| Wells Fargo | 10 Jul 2025 | 129.00 (34.29%) | Buy | 89.04 |
| Needham | 09 Jul 2025 | 95.00 (-1.10%) | Buy | 89.00 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |